# Martin Dreyling

Source: https://onco.cc/people/martin-dreyling/  
OnCo record `martin-dreyling` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients.

## Summary

Martin Dreyling leads the European Mantle Cell Lymphoma Network, whose MCL Younger and Elderly trials established cytarabine-based induction with autologous transplant and rituximab maintenance, and was principal investigator of TRIANGLE, which showed adding ibrutinib to first-line therapy improves outcomes and that transplant adds nothing once ibrutinib is given, a shift toward chemotherapy-light care. He chairs ESMO lymphoma guideline work.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; mantle-cell; cooperative-group
- Role: Professor of Medicine and Head of the Lymphoma Program, LMU University Hospital Munich; Chair, European MCL Network
- Specialisms: Mantle cell lymphoma; First-line therapy; BTK inhibitors; European cooperative trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Dreyling%20M%5BAuthor%5D%20mantle%20cell%20lymphoma

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [CD20](https://onco.cc/targets/cd20/)
- institutions: [LMU Klinikum München](https://onco.cc/institutions/lmu-munich/)
- trials: [ELARA](https://onco.cc/trials/elara/), [SHINE](https://onco.cc/trials/shine/)
- key papers: [Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma](https://onco.cc/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/), [Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma](https://onco.cc/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/), [Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial](https://onco.cc/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/martin-dreyling.json